KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Impact of Intravesical Bacillus Calmette-Guérin Therapy Following Transurethral En Bloc Resection of Bladder Tumour: Post Hoc Analysis of a Randomised, Multicentre, Phase 3 Trial.

Jeremy Yuen-Chun Teoh, Chris Ho-Ming Wong, Cheung-Hing Cheng, Chiu-Fung Tsang, Joseph Kai-Man Li, Bryan Kwun-Chung Cheng, Wilson Hoi-Chak Chan, Wayne Kwun-Wai Chan, Trevor Churk-Fai Li, Yi Chiu, Man-Chung Law, Clarence Lok-Hei Leung, Brian Sze-Ho Ho, Chris Yue-Kit Lee, Ronald Cheong-Kin Chan, Eddie Shu-Yin Chan, Tsz-Yeung Chan, James Hok-Leung Tsu, Ho-Man Tam, Kin-Man Lam, Hing-Shing So, Chak-Lam Cho, Chi-Man Ng, Chun-Ki Chan, Pak-Ling Liu, Ringo Wing-Hong Chu, Ada Tsui-Lin Ng, Sau-Kwan Chu, Chi-Hang Yee, Ming-Kwong Yiu, Ka-Lun Lo, Wing-Hang Au, Wai-Kit Ma, Peter Ka-Fung Chiu, Hilda Sze-Wan Kwok, Siu-Ying Yip, Chi-Ho Leung, Chi-Fai Ng, EB-StaR Study Group

Eur Urol Oncol S2588-9311(25)00245-7

PMID41177716
PMCID-
DOI10.1016/j.euo.2025.09.008
发表日期2025-11-02
摘要

摘要

We conducted a post hoc analysis of the EB-StaR study (NCT02993211) to assess the impact of intravesical bacillus Calmette-Guérin (BCG) therapy following en bloc resection of bladder tumour (ERBT) or standard resection (SR) in patients with non-muscle-invasive bladder cancer (NMIBC). The outcome measures were the 1-yr recurrence and progression rates. Among the 276 patients included in the analysis, 1-yr recurrence rates were 33% (95% confidence interval [CI] 21-43%) in the ERBT alone group versus 41% (95% CI 30-50%) in the SR alone group (p = 0.02); and 5% (95% CI 0-14%) in the ERBT + BCG group versus 26% (95% CI 5.8-42%) in the SR + BCG group (p = 0.059). The 1-yr progression rates were 0% in the ERBT alone group versus 2% (95% CI 0-4.6%) in the SR alone group (p = 0.13); and 0% in the ERBT + BCG group versus 5.6% (95% CI 0-16%) in the SR + BCG group (p = 0.4). The combination of ERBT and intravesical BCG therapy appeared to yield excellent oncological control, resulting in a 1-yr recurrence rate of 5% among patients with high-risk NMIBC. Good-quality surgery plus good adjuvant therapy should be considered vital components in optimising long-term oncological outcomes in NMIBC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。